LSD Could Lift Anxiety In The Terminally Ill, Finds The First Study Of The Hallucinogenic In 40 Years
Wait, did the '60s have it right about LSD after all? The first controlled trial of the hallucinogenic in four decades has found that LSD could help lift chronic anxiety in some terminally-ill patients, and so could possibly be used therapeutically. But don't get too excited just yet: The study was small-scale, utilizing only 12 patients, and four of them — those who had lower doses of LSD than the rest — ended up with worsened anxiety a year later. Still, it's an interesting look into possible applications of hallucinogenic drugs.
The Swiss study, published in The Journal of Nervous and Mental Disease and sponsored by the Multidisciplinary Association for Psychedelic Studies, examined 12 patients suffering from extreme anxiety caused by illnesses. Most of the participants had terminal cancer. All held weekly psychotherapy sessions for two months with study author Dr. Peter Gasser.
Initially, they attended sessions where no drugs were introduced, but eventually, all participants had two full-day psychotherapy sessions in which LSD was administered. Eight of the patients received a "full dose" of LSD, which was 200 micrograms; the other four received the "placebo" or just 20 micrograms of LSD
And the study's results?
- The eight participants with the full dose saw anxiety levels improve by 20 percent a year after the LSD was administered.
- The other four participants, who had lower doses, ended up with worsened anxiety actually.
- Researchers measured these anxiety levels by evaluating the patients' "state" and "trait" anxiety scores — "state" meaning anxiety influenced by changing circumstances, "trait" meaning anxiety that was a personality's stable characteristic.
This study is another example of a growing trend of research into the therapeutic possibilities of therapeutic possibilities of hallucinogens. Recently, some American psychiatrists have called for the States to end its ban on psychoactive drug research, including Special K, MDMA, and LSD.
As Scientific American 's editors wrote a month ago:
“New thinking is desperately needed to aid the estimated 14 million American adults who suffer from severe mental illness. If some of the obstacles to research can be overcome, it may be possible to finally detach research on psychoactive chemicals from the hyperbolic rhetoric that is a legacy of the war on drugs.”